Lung cancer: current diagnosis and treatment
- PMID: 20038979
- PMCID: PMC2797332
- DOI: 10.3238/arztebl.2009.0809
Lung cancer: current diagnosis and treatment
Abstract
Background: Much progress has been made in the treatment of lung cancer in the last ten years (adjuvant chemotherapy, targeted therapy, individualized therapy). Nonetheless, lung cancer is still the leading cause of death due to cancer and thus remains a major medical, scientific, and social problem.
Method: This review is based on national and international recommendations and selected articles from the literature.
Results: Cigarette smoking is the major pathogenic factor for lung cancer. Lung cancer can be divided into two major types that differ in their biological behavior, small cell lung cancer and non-small cell lung cancer. Whenever possible, the diagnosis should be confirmed by biopsy, the extent of disease should be documented in detail (international TNM classification/staging), and the patient's functional level should be assessed with a view toward treatment planning. Surgery for non-small cell lung cancer with curative intent is possible up to stage IIIA, while stage IIIB is the domain of radiotherapy. Surgery for small cell lung cancer with curative intent is possible for rare cases in early stages (T1N0 and T2N0, i.e., stage IA and IB). As long as small cell lung cancer is restricted to one side of the chest, simultaneous radiation therapy and chemotherapy are indicated. If a malignant pleural effusion or distant metastases are present, both lung cancers are treated palliatively with platinum-based chemotherapy.
Keywords: cigarette smoking; diagnosis; lung cancer; targeted therapy; treatment.
Figures
Comment in
-
Correspondence (letter to the editor): Palliative treatment and palliative care.Dtsch Arztebl Int. 2010 Oct;107(41):728; author reply 728-9. doi: 10.3238/arztebl.2010.0728b. Epub 2010 Oct 15. Dtsch Arztebl Int. 2010. PMID: 21046004 Free PMC article. No abstract available.
-
Correspondence (letter to the editor): Treatment option should not be withheld.Dtsch Arztebl Int. 2010 Oct;107(41):728; author reply 728-9. doi: 10.3238/arztebl.2010.0728a. Epub 2010 Oct 15. Dtsch Arztebl Int. 2010. PMID: 21046005 Free PMC article. No abstract available.
Similar articles
-
[Lung cancer].Internist (Berl). 2006 Jun;47(6):611-20; quiz 621. doi: 10.1007/s00108-006-1581-3. Internist (Berl). 2006. PMID: 16767476 Review. German.
-
Correspondence (letter to the editor): Treatment option should not be withheld.Dtsch Arztebl Int. 2010 Oct;107(41):728; author reply 728-9. doi: 10.3238/arztebl.2010.0728a. Epub 2010 Oct 15. Dtsch Arztebl Int. 2010. PMID: 21046005 Free PMC article. No abstract available.
-
Correspondence (letter to the editor): Palliative treatment and palliative care.Dtsch Arztebl Int. 2010 Oct;107(41):728; author reply 728-9. doi: 10.3238/arztebl.2010.0728b. Epub 2010 Oct 15. Dtsch Arztebl Int. 2010. PMID: 21046004 Free PMC article. No abstract available.
-
Correspondence (letter to the editor): Radon balneology.Dtsch Arztebl Int. 2010 Oct;107(41):730; author reply 732. doi: 10.3238/arztebl.2010.0730a. Epub 2010 Oct 15. Dtsch Arztebl Int. 2010. PMID: 21046007 Free PMC article. No abstract available.
-
[Small cell lung cancer].Wien Klin Wochenschr. 2007;119(23-24):697-710. doi: 10.1007/s00508-007-0913-1. Wien Klin Wochenschr. 2007. PMID: 18157602 Review. German.
Cited by
-
Implantation of permanent pleural catheter for palliation of malignant pleural effusion.Cancer Manag Res. 2016 Nov 8;8:129-133. doi: 10.2147/CMAR.S107747. eCollection 2016. Cancer Manag Res. 2016. PMID: 27877066 Free PMC article.
-
A regulatory loop involving miR-29c and Sp1 elevates the TGF-β1 mediated epithelial-to-mesenchymal transition in lung cancer.Oncotarget. 2016 Dec 27;7(52):85905-85916. doi: 10.18632/oncotarget.13137. Oncotarget. 2016. PMID: 27829234 Free PMC article.
-
Unraveling the therapeutic mechanisms of dichloroacetic acid in lung cancer through integrated multi-omics approaches: metabolomics and transcriptomics.Front Genet. 2023 Jun 8;14:1199566. doi: 10.3389/fgene.2023.1199566. eCollection 2023. Front Genet. 2023. PMID: 37359381 Free PMC article.
-
Matrix Metalloproteinases and Stress Hormones in Lung Cancer Progression.J Oncol. 2022 Sep 29;2022:5349691. doi: 10.1155/2022/5349691. eCollection 2022. J Oncol. 2022. PMID: 36213817 Free PMC article.
-
Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer.BMC Cancer. 2016 Aug 5;16:603. doi: 10.1186/s12885-016-2646-x. BMC Cancer. 2016. PMID: 27495736 Free PMC article.
References
-
- Brambilla E, Lantuejoul S. Pathology and immunhistochemistry of lung cancer. Eur Resp Monogr. 2009;44:15–35.
-
- Batzler WU, Giersiepen K, Hentschel S, et al. Robert Koch Institut, V. GdeKiDe. Contributions to Federal Health Reporting. Berlin: Mercedes Druck; 2008. Cancer in Germany, 2003-2004 Incidence and Trends.
-
- Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. Chest. ((2nd edition)) 2007;132:29–55. - PubMed
-
- Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP -evidence-based clinical practice guidelines. Chest. ((2nd edition)) 2007;132:131–148. - PubMed
-
- Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–1717. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials